The cultured meat industry is a young but revolutionary industry, with the potential to change agricultural practices and human meat consumption as we know it. Cultured meat refers to meat created using cell culture techniques within a laboratory or manufacturing facility. It is produced by growing stem cells collected from cattle, chicken, pigs, fish, lamb, and other livestock and then differentiating them into the various meat components, such as muscle (myocytes) and fat (adipose) tissue. [Read more…]
Eli Lilly Commits Up to $2.4B to Orna Therapeutics in Major Bet on In Vivo CAR-T
In news announced yesterday (February 9, 2026), Eli Lilly revealed plans to acquire Orna Therapeutics for up to $2.4 billion, a truly staggering price tag. The move marks a decisive step toward the next generation of cell therapy: programming immune cells directly inside the patient rather than manufacturing them outside the body.
Importantly, this transaction is not centered on a single pipeline candidate, but on securing a platform technology that could reshape how CAR-T and other immune-reset strategies are developed and delivered across autoimmune disease and beyond. [Read more…]
The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy
What do we know of the safety and efficacy of stem cell therapeutics? Over 50 years have passed since the discovery of hematopoietic stem cells (bone marrow transplantation to cure diseases such as leukemia), over 24 years since the discovery of human embryonic stem cells (hESC), and 18 years since the discovery of induced pluripotent stem cells (iPS cells). There are now thousands of stem cell trials underway in clinics worldwide. Despite this experience, what do we actually know about the safety and efficacy of stem cell therapeutics? [Read more…]
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering
Across 2025, a striking trend has emerged in biotechnology. Major pharmaceutical companies are racing to acquire in vivo cell engineering platforms, signaling that reprogramming cells inside the body has moved from speculative science to strategic priority.
In just a few months, the field has transformed. AstraZeneca, AbbVie, Gilead’s Kite Pharma, and Bristol Myers Squibb have all made acquisitions designed to accelerate their capabilities in in vivo cell therapy. Each deal highlights the growing importance of technologies that can directly engineer immune cells without removing them from the body. [Read more…]
FDA Grants RMAT to iRegene’s NouvNeu001, Making It World’s First iPSC Therapy with FTD and RMAT Recognitions
Designation underscores potential of chemically induced, off-the-shelf cell therapy to address high unmet need in Parkinson’s disease, following compelling Phase I clinical data
CHENGDU, China, Jan. 19, 2026 — iRegene Therapeutics Co., Ltd. (“iRegene” or the “Company”), a biotechnology company pioneering chemically induced allogeneic cell therapy, today announced that its lead product, NouvNeu001, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for the treatment of Parkinson’s disease (PD). [Read more…]
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 334
- Next Page »